VERA vs. GERN, ARVN, ZLAB, RCKT, AMRX, DCPH, PTCT, INDV, ACAD, and DYN
Should you be buying Vera Therapeutics stock or one of its competitors? The main competitors of Vera Therapeutics include Geron (GERN), Arvinas (ARVN), Zai Lab (ZLAB), Rocket Pharmaceuticals (RCKT), Amneal Pharmaceuticals (AMRX), Deciphera Pharmaceuticals (DCPH), PTC Therapeutics (PTCT), Indivior (INDV), ACADIA Pharmaceuticals (ACAD), and Dyne Therapeutics (DYN). These companies are all part of the "pharmaceutical preparations" industry.
Geron (NASDAQ:GERN) and Vera Therapeutics (NASDAQ:VERA) are both mid-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, community ranking, profitability, dividends, valuation, analyst recommendations, earnings and media sentiment.
73.7% of Geron shares are owned by institutional investors. Comparatively, 99.2% of Vera Therapeutics shares are owned by institutional investors. 3.1% of Geron shares are owned by company insiders. Comparatively, 21.7% of Vera Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Geron presently has a consensus price target of $6.10, suggesting a potential upside of 60.10%. Vera Therapeutics has a consensus price target of $36.71, suggesting a potential downside of 11.30%. Given Vera Therapeutics' higher possible upside, research analysts plainly believe Geron is more favorable than Vera Therapeutics.
Geron has a beta of 0.55, indicating that its share price is 45% less volatile than the S&P 500. Comparatively, Vera Therapeutics has a beta of 1.11, indicating that its share price is 11% more volatile than the S&P 500.
In the previous week, Vera Therapeutics had 8 more articles in the media than Geron. MarketBeat recorded 11 mentions for Vera Therapeutics and 3 mentions for Geron. Geron's average media sentiment score of 1.13 beat Vera Therapeutics' score of 0.68 indicating that Vera Therapeutics is being referred to more favorably in the news media.
Geron received 455 more outperform votes than Vera Therapeutics when rated by MarketBeat users. Likewise, 69.52% of users gave Geron an outperform vote while only 54.55% of users gave Vera Therapeutics an outperform vote.
Vera Therapeutics has lower revenue, but higher earnings than Geron. Vera Therapeutics is trading at a lower price-to-earnings ratio than Geron, indicating that it is currently the more affordable of the two stocks.
Vera Therapeutics has a net margin of 0.00% compared to Vera Therapeutics' net margin of -38,730.00%. Geron's return on equity of -52.43% beat Vera Therapeutics' return on equity.
Summary
Vera Therapeutics beats Geron on 12 of the 18 factors compared between the two stocks.
Get Vera Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for VERA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VERA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Vera Therapeutics Competitors List
Related Companies and Tools
